country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-P9932

Copy Link Print Information

Obiltoxaximab

(別名: ETI 204)

カスタマーレビュー

Based on 1 Customer Validation

Obiltoxaximab (ETI 204) is the second and potent anti-protective antigen (PA) monoclonal antibody with immunogenicity. Obiltoxaximab plays a central role in anthrax toxin assembly and target cell intoxication, promoting survival, and inhibiting bacterial spread to the periphery in animal models. Obiltoxaximab can be used in the research of inhalational anthrax, bacteremia and toxemia.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.06%
CAS 番号: 1351337-07-9
分子量:145.5 kDa

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Obiltoxaximab 構造式

CAS 番号: 1351337-07-9

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- 体内実験
- 臨床実験
- 遺伝子ID
- アクセッション番号
- Conjugated
- Reconsititution
- Format
- アプリケーション
化学情報
純度とドキュメンテーション
参考文献
Calculators
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target

anthrax protective antigen

体内実験

Obiltoxaximab (16 mg/kg, i.v., a single dose for 70 days) for simulated populations of healthy and infected humans is comparable in overall serum exposures in individual infected macaques following obiltoxaximab, similar results in rabbit experiments^[1].
Obiltoxaximab (16 mg/kg, i.m., 24, 48, 72 h prior to lethal challenge with B. anthracis spores) leads to 100% survival challenged with B. anthracis spores in cynomolgus macaques and prevents systemic bacteremia in the vast majority of animals^[2].
Obiltoxaximab (4 and 8 mg/kg, i.v. and i.m., a single dose for 9 h) postexposure prophylaxis (PEP) leads to 100% survival with the combination of Levofloxacin (HY-B0330) challenged with B. anthracis spores in rabbits^[2].
Obiltoxaximab (8 mg/kg, i.v., a single dose, 29 days) combined with antibiotics or Doxycycline (HY-N0565) lowers bacteremia levels in protective antigen (PA) of anthrax induced rabbits^[5].

Pharmacokinetics of intramuscular Obiltoxaximab^[2]

Study and dose (mg/kg)	Postchallenge dosing schedule	C_max (μg/mL)	T_max (days)	AUC_0-∞ (μg·day/mL)	T_1/2 (days)	CL /F(mL/day/kg)	V_z/F (mL/kg)
PEP 2
8	18 h	80.8	1.0	1030	7.50	7.76	84.0
8	24 h	86.5	1.0	788	5.20	10.2	76.2
16	18 h	165	1.0	2120	8.44	7.54	91.9
16	24 h	119	1.0	1990	9.85	8.03	114
PEP 3
16	24 h	142	1.0	2190	10.4	7.00	110
16	36 h	132	0.50	1540	7.09	10.0	106
16	48 h	104	3.0	2040	12.6	8.00	143

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Human, macaques and rabbits^[1]
Dosage:

16 mg/kg
Administration:

i.v., a single dose, 70 days
Result:

Overall serum exposures were comparable following obiltoxaximab in human, macaques and rabbits.

Animal Model:

Cynomolgus macaques^[2]
Dosage:

16 mg/kg
Administration:

i.m., 24, 48, 72 h prior to lethal challenge with B. anthracis spores
Result:

Resulted in transient low levels of bacteremia in several animals, resolving in all animals after day 4, and the majority of animals remained abacteremic until day 56.

Animal Model:

Rabbits^[2]
Dosage:

4 and 8 mg/kg
Administration:

i.v. and i.m. at 4 and 8 mg/kg, a single dose, 9 h
Result:

Effectiveness in the PEP setting was initially examined in rabbits.

Animal Model:

Protective antigen (PA) of anthrax induced rabbits^[5]
Dosage:

8 mg/kg
Administration:

i.v., a single dose, 29 days
Result:

Lowered bacteremia levels between days 1 and 2 combined with antibiotics, eliminated bacteremia levels combined with Doxycycline (HY-N0565) in protective antigen (PA) of anthrax induced rabbits.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

遺伝子ID

45025512 [NCBI]

アクセッション番号

P13423

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

Human IgG1 kappa

アプリケーション

ELISA, FACS, Functional assay

化学情報

CAS 番号 1351337-07-9
性状 Liquid
分子量 145.5 kDa
Color Colorless to light yellow
SMILES

[Obiltoxaximab]
別名

ETI 204
輸送条件

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (266 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

参考文献

[1]. Nagy CF, et al. Animal-to-Human Dose Translation of Obiltoxaximab for Treatment of Inhalational Anthrax Under the US FDA Animal Rule. Clin Transl Sci. 2017 Jan;10(1):12-19. [Content Brief]

[2]. Yamamoto BJ, et al. Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5796-805. [Content Brief]

[3]. Hou A W, et al. Obiltoxaximab: adding to the treatment arsenal for Bacillus anthracis infection[J]. Annals of Pharmacotherapy, 2017, 51(10): 908-913. [Content Brief]

[4]. Yamamoto B J, et al. Obiltoxaximab prevents disseminated Bacillus anthracis infection and improves survival during pre-and postexposure prophylaxis in animal models of inhalational anthrax[J]. Antimicrobial agents and chemotherapy, 2016, 60(10): 5796-5805. [Content Brief]

[5]. Biron B, et al. Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax[J]. Antimicrob Agents Chemother. 2015 Apr;59(4):2206-14. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ

Amount: USD 0.00

生物活性
- 製品説明
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- 体内実験
- 臨床実験
- 遺伝子ID
- アクセッション番号
- Conjugated
- Reconsititution
- Format
- アプリケーション
化学情報
純度とドキュメンテーション
参考文献

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Obiltoxaximab

Cell-ATP Viability Detection Kit

Protein A Agarose

HOLO Human Interleukin-2 (IL-2) Detection Kit

Bradford Protein Assay Kit

PBS Buffer (1×)

DPBS Buffer (1×)

Cytotoxicity LDH Assay Kit

Antibody Inhibitor Library

生物活性

化学情報

純度とドキュメンテーション

参考文献

Calculators

Help & FAQs

Obiltoxaximab 関連分類

HY-P9932 関連分類